ASTCT

As we approach the Thanksgiving season, Margy MacMillan, MD, MSc, FRCPC, reminds us of the privilege of caring for patients and the power of the community that makes transplantation and cellular therapy possible. Read on Nucleus the latest President’s Message on gratitude, collaboration, and the shared mission that drives ASTCT members every day. ow.ly/YoJ45105aNF

ASTCT is now accepting Volunteer applications for multiple committees making an impact across the Society. The Call for Volunteers closes soon on Nov. 13. Learn more and submit your interest: ow.ly/kvg75105aI2

As cellular therapies expand across hematologic malignancies, solid tumors, and autoimmune diseases, understanding and managing treatment-related toxicities has never been more important. In this Healio Q&A, Sergio A. Giralt, MD, FACP, FASTCT discusses the upcoming 5th International Conference on Toxicities of Transplantation and Cellular Therapies taking place on Nov. 13-14 in Chicago, highlighting emerging toxicities, multidisciplinary approaches to toxicity management, care for older adults, and the research needed to improve the safety and tolerability of transplantation and cellular therapies. Read more: ow.ly/BF225105atL

Join the ASTCT Pharmacy SIG on Nov. 18 for the next Pharmacy Journal Club as Drs. Hosick and Robida present two articles related to: •CRISPR-Cas9 gene-edited allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in acute myeloid leukemia (AML) •Azacitidine-venetoclax versus induction chemotherapy for the treatment of acute myeloid leukemia (AML) Register: ow.ly/q66W5105bzg

New from ASTCT: ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy. This consensus document establishes standardized grading criteria for toxicities associated with immune effector cell therapies, supporting consistency across clinical practice, research and reporting. Read the full publication: astctjournal.org/article/S26…

ASTCT is now accepting Volunteer applications for multiple committees making an impact across the Society. The Call for Volunteers closes soon on Nov. 13. Learn more and submit your interest: ow.ly/RJms5105aI5

New on ASTCT Nucleus: What are the long-term outcomes of donor lymphocyte infusion (DLI) for patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation? A 20-year follow-up study found that DLI can produce durable remissions in a subset of patients with low-burden relapse, while outcomes remain poor for those with higher disease burden at relapse. The findings provide an important benchmark for evaluating emerging post-transplant salvage approaches and reinforce the importance of disease burden in treatment outcomes. Read more: ow.ly/9APf5105a7H

Travel Award Alert: Need funding to attend #Tandem27? Select ASTCT Special Interest Groups are offering travel awards to help cover the cost of meeting expenses. Open to Advanced Practice Professional, Nursing and Pharmacy SIG members. Deadline: December 12, 2026 Apply now: ow.ly/vctJ5105a3S

Join Claudio Brunstein, MD for Harnessing Cellular Therapies Beyond Cancer: The Autoimmune Expansion at #Tandem27. Discover how cellular immunotherapy is transforming the treatment of autoimmune diseases, from CAR T-cell therapies and immune tolerance to emerging clinical applications and collaborative care models. See the full session list: ow.ly/B1CC5103Wcm Register: ow.ly/HGFX5103Wco

Presenting research at Tandem 2027? Travel grant opportunities can help support attendance and provide additional visibility for emerging investigators and trainees. Deadline: Dec. 14. Learn more and apply. 🔗 ow.ly/xiHu5101oTQ

Your ASTCT membership supports your work all year long with access to education, clinical resources, networking opportunities and a community dedicated to advancing transplantation and cellular therapy. Renew today to keep your benefits going into the new year. 🔗 astct.org/join

Behind every ASTCT program, initiative, and resource is a dedicated group of volunteers. Be part of the team helping move the field forward. 🔗 ow.ly/hGMz5101oQR

As cell therapies expand into autoimmune diseases and solid tumors, new safety considerations and clinical challenges continue to emerge. Join Ran Reshef, MD, MSc, of Columbia University Irving Medical Center for a timely session exploring emerging toxicities, management strategies and key safety considerations as cellular therapies move beyond hematologic malignancies. Register now: 🔗 ow.ly/KLgE5101oJc

Can off-the-shelf regulatory T-cell (Treg) therapy help prevent graft-versus-host disease (GVHD)? In this first-in-human study, investigators evaluated gp120-activated allogeneic regulatory T cells (ATreg) derived from HLA-unmatched donors as a novel approach to GVHD prevention after allogeneic hematopoietic cell transplantation. The findings demonstrated successful engraftment, no infusion-related toxicities, and no grade 3-4 acute GVHD within the first 100 days after transplant. Read more: ow.ly/UlkR5101oA0

Take ASTCT guidelines wherever you go. 📱 Access resources on GVHD, conditioning regimens, stem cell collection and mobilization, supportive care, survivorship, HCT and more with the free ASTCT Practice Guideline App. Download today: ow.ly/Yetw5101owO

Looking for support to attend Tandem 2027? SIG Travel Grants help members participate in the meeting, connect with peers, and engage more deeply with the ASTCT community and are awarded to selected members of the following Special Interest Groups (SIGs) to allay the costs of attending the 2027 Tandem Meetings: ✅ Advanced Practice Professional ✅ Nursing ✅ Pharmacy ✅ Social Work Apply now: 🔗ow.ly/FVWH5101o4a

Choosing a conditioning approach means weighing more than intensity alone. How do available RTC approaches compare? What trade-offs should factor into regimen selection? And how can patient- and disease-specific characteristics help guide your decision? Reduced-Toxicity Conditioning Treatments: What Clinicians Need to Know Now explores the evidence behind conditioning approaches and strengthens your ability to differentiate among available options. ow.ly/qZ0W50ZPMUl #AML #MDS #StemCellTransplant #Hematology #MedicalEducation #AlloHCT

How often do serious treatment-related toxicities occur after patients leave the hospital following lifileucel therapy for advanced melanoma? A new study found that severe outpatient toxicities were uncommon after discharge, suggesting that follow-up requirements for tumor-infiltrating lymphocyte (TIL) therapy may differ from the intensive monitoring strategies often used for CAR T-cell therapy. The findings provide important insights into post-treatment care, readmissions, and patient monitoring as TIL therapy continues to expand. Read more: ow.ly/uNNR5101nPZ

Transplant is a team sport, and #Tandem27 has education designed for everyone on that team. Explore the 2027 program to find agendas for role-specific and specialty tracks at the meetings: ow.ly/yCAn5101nOE

New from Healio and ASTCT The treatment landscape for classical Hodgkin lymphoma continues to evolve with the introduction of novel agents and changing transplantation strategies. In this Healio Q&A, Sairah Ahmed, MD, discusses ASTCT’s updated clinical practice recommendations, including the role of autologous transplantation, integration of brentuximab vedotin and checkpoint inhibitors, maintenance approaches, and current considerations for allogeneic transplantation. Explore how these evidence-based recommendations are helping clinicians navigate the modern management of relapsed or refractory classical Hodgkin lymphoma. Read more: ow.ly/6vYJ5101nGp